Tony Fitzgerald
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tony Fitzgerald has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Harry Comber
Cork Specialist Training Programme for General Practice, University College Cork, 3 Bloomfield, Cork, Ireland
3 shared publications- Josephine Hegarty
Catherine McAuley School of Nursing and Midwifery University College Cork Cork Ireland
3 shared publications Paul V Beirne
University College Cork Department of Epidemiology and Public Health 4th Floor, Western Gateway Building, Western Road Cork Ireland
3 shared publicationsEileen Fitzgerald
Newmarket, Cork, Ireland
2 shared publications- Eileen Savage
Catherine McAuley School of Nursing and Midwifery, University College Cork, Cork, Ireland
2 shared publications Fiona MacLeod
University College Cork; Department of Epidemiology and Public Health; 4th Floor, Western Gateway Building, Western Road Cork Ireland
2 shared publications
Latest Publications
- Open Access
- 13 September 2022
- Published by JMIR Publications Inc. in JMIR Bioinformatics and Biotechnology
- Vol. 3 (1) , e38845
Reducing Crowding in Emergency Departments With Early Prediction of Hospital Admission of Adult Patients Using Biomarkers Collected at Triage: Retrospective Cohort Study
Background: Emergency department crowding continues to threaten patient safety and cause poor patient outcomes. Prior models designed to predict hospital admission have had biases. Predictive models that successfully estimate the probability of patient hospital admission would be useful in reducing or preventing emergency department “boarding” and hospital “exit block” and would reduce emergency department crowding by initiating earlier hospital admission and avoiding protracted bed procurement processes. Objective: To develop a model to predict imminent adult patient hospital admission from the emergency department early in the patient visit by utilizing existing clinical descriptors (ie, patient biomarkers) that are routinely collected at triage and captured in the hospital’s electronic medical records. Biomarkers are advantageous for modeling due to their early and routine collection at triage; instantaneous availability; standardized definition, measurement, and interpretation; and their freedom from the confines of patient histories (ie, they are not affected by inaccurate patient reports on medical history, unavailable reports, or delayed report retrieval). Methods: This retrospective cohort study evaluated 1 year of consecutive data events among adult patients admitted to the emergency department and developed an algorithm that predicted which patients would require imminent hospital admission. Eight predictor variables were evaluated for their roles in the outcome of the patient emergency department visit. Logistic regression was used to model the study data. Results: The 8-predictor model included the following biomarkers: age, systolic blood pressure, diastolic blood pressure, heart rate, respiration rate, temperature, gender, and acuity level. The model used these biomarkers to identify emergency department patients who required hospital admission. Our model performed well, with good agreement between observed and predicted admissions, indicating a well-fitting and well-calibrated model that showed good ability to discriminate between patients who would and would not be admitted. Conclusions: This prediction model based on primary data identified emergency department patients with an increased risk of hospital admission. This actionable information can be used to improve patient care and hospital operations, especially by reducing emergency department crowding by looking ahead to predict which patients are likely to be admitted following triage, thereby providing needed information to initiate the complex admission and bed assignment processes much earlier in the care continuum.
- 13 September 2022
- Published by JMIR Publications Inc. in JMIR Bioinformatics and Biotechnology
- Vol. 3 (1) , e38845
Open AccessReducing Crowding in Emergency Departments With Early Prediction of Hospital Admission of Adult Patients Using Biomarkers Collected at Triage: Retrospective Cohort Study
Background: Emergency department crowding continues to threaten patient safety and cause poor patient outcomes. Prior models designed to predict hospital admission have had biases. Predictive models that successfully estimate the probability of patient hospital admission would be useful in reducing or preventing emergency department “boarding” and hospital “exit block” and would reduce emergency department crowding by initiating earlier hospital admission and avoiding protracted bed procurement processes. Objective: To develop a model to predict imminent adult patient hospital admission from the emergency department early in the patient visit by utilizing existing clinical descriptors (ie, patient biomarkers) that are routinely collected at triage and captured in the hospital’s electronic medical records. Biomarkers are advantageous for modeling due to their early and routine collection at triage; instantaneous availability; standardized definition, measurement, and interpretation; and their freedom from the confines of patient histories (ie, they are not affected by inaccurate patient reports on medical history, unavailable reports, or delayed report retrieval). Methods: This retrospective cohort study evaluated 1 year of consecutive data events among adult patients admitted to the emergency department and developed an algorithm that predicted which patients would require imminent hospital admission. Eight predictor variables were evaluated for their roles in the outcome of the patient emergency department visit. Logistic regression was used to model the study data. Results: The 8-predictor model included the following biomarkers: age, systolic blood pressure, diastolic blood pressure, heart rate, respiration rate, temperature, gender, and acuity level. The model used these biomarkers to identify emergency department patients who required hospital admission. Our model performed well, with good agreement between observed and predicted admissions, indicating a well-fitting and well-calibrated model that showed good ability to discriminate between patients who would and would not be admitted. Conclusions: This prediction model based on primary data identified emergency department patients with an increased risk of hospital admission. This actionable information can be used to improve patient care and hospital operations, especially by reducing emergency department crowding by looking ahead to predict which patients are likely to be admitted following triage, thereby providing needed information to initiate the complex admission and bed assignment processes much earlier in the care continuum.
- 10 February 2017
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (2) , CD011396
Interventions for raising breast cancer awareness in women
Breast cancer continues to be the most commonly diagnosed cancer in women globally. Early detection, diagnosis and treatment of breast cancer are key to better outcomes. Since many women will discover a breast cancer symptom themselves, it is important that they are breast cancer aware i.e. have the knowledge, skills and confidence to detect breast changes and present promptly to a healthcare professional. To assess the effectiveness of interventions for raising breast cancer awareness in women. We searched the Cochrane Breast Cancer Group's Specialised Register (searched 25 January 2016), Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 12) in the Cochrane Library (searched 27 January 2016), MEDLINE OvidSP (2008 to 27 January 2016), Embase (Embase.com, 2008 to 27 January 2016), the World Health Organization’s International Clinical Trials Registry Platform (ICTRP) search portal and ClinicalTrials.gov (searched 27 Feburary 2016). We also searched the reference lists of identified articles and reviews and the grey literature for conference proceedings and published abstracts. No language restriction was applied. Randomised controlled trials (RCTs) focusing on interventions for raising women’s breast cancer awareness i.e. knowledge of potential breast cancer symptoms/changes and the confidence to look at and feel their breasts, using any means of delivery, i.e. one-to-one/group/mass media campaign(s). Two authors selected studies, independently extracted data and assessed risk of bias. We reported the odds ratio (OR) and 95% confidence intervals (CIs) for dichotomous outcomes and mean difference (MD) and standard deviation (SD) for continuous outcomes. Since it was not possible to combine data from included studies due to their heterogeneity, we present a narrative synthesis. We assessed the quality of evidence using GRADE methods. We included two RCTs involving 997 women: one RCT (867 women) randomised women to receive either a written booklet and usual care (intervention group 1), a written booklet and usual care plus a verbal interaction with a radiographer or research psychologist (intervention group 2) or usual care (control group); and the second RCT (130 women) randomised women to either an educational programme (three sessions of 60 to 90 minutes) or no intervention (control group). Knowledge of breast cancer symptoms In the first study, knowledge of non-lump symptoms increased in intervention group 1 compared to the control group at two years postintervention, but not significantly (OR 1.1, 95% CI 0.7 to 1.6; P = 0.66; 449 women; moderate-quality evidence). Similarly, at two years postintervention, knowledge of symptoms increased in the intervention group 2 compared to the control group but not significantly (OR 1.4, 95% CI 0.9 to 2.1; P = 0.11; 434 women; moderate-quality evidence). In the second study, women’s awareness of breast cancer symptoms had increased one month post intervention in the educational group (MD 3.45, SD 5.11; 65 women; low-quality evidence) compared to the control group (MD −0.68, SD 5.93; 65 women; P < 0.001), where there was a decrease in awareness. Knowledge of age-related risk In the first study, women’s knowledge of age-related risk of breast cancer increased, but not significantly, in intervention group 1 compared to control at two years postintervention (OR 1.8; 95% CI 0.9 to 3.5; P < 0.08; 447 women; moderate-quality evidence). Women's knowledge of risk increased significantly in intervention group 2 compared to control at two years postintervention (OR 4.8, 95% CI 2.6 to 9.0; P < 0.001; 431 women; moderate-quality evidence). In the second study, women’s perceived susceptibility (how at risk they considered themselves) to breast cancer had increased significantly one month post intervention in the educational group (MD 1.31, SD 3.57; 65 women; low-quality evidence) compared to the control group (MD −0.55, SD 3.31; 65 women; P = 0.005), where a decrease in perceived susceptibility was noted. Frequency of Breast Checking In the first study, no significant change was noted for intervention group 1 compared to control at two years postintervention (OR 1.1, 95% CI 0.8 to 1.6; P = 0.54; 457 women; moderate-quality evidence). Monthly breast checking increased, but not significantly, in intervention group 2 compared to control at two years postintervention (OR 1.3, 95% CI 0.9 to 1.9; P = 0.14; 445 women; moderate-quality evidence). In the second study, women’s breast cancer preventive behaviours increased significantly one month post intervention in the educational group (MD 1.21, SD 2.54; 65 women; low-quality evidence) compared to the control group (MD 0.15, SD 2.94; 65 women; P < 0.045). Breast Cancer Awareness Women’s overall breast cancer awareness did not change in intervention group 1 compared to control at two years postintervention (OR 1.8, 95% CI 0.6 to 5.30; P = 0.32; 435 women; moderate-quality evidence) while overall awareness increased in the intervention group 2 compared to control at two years postintervention (OR 8.1, 95% CI 2.7 to 25.0; P < 0.001; 420 women; moderate-quality evidence). In the second study, there was a significant increase in scores on the Health Belief Model (that included the constructs of awareness and perceived susceptibility) at one month postintervention in the educational group (mean 1.21, SD 2.54; 65 women) compared to the control group (mean 0.15, SD 2.94; 65 women; P = 0.045). Neither study reported outcomes relating to motivation to check their breasts, confidence to seek help, time from breast symptom discovery to presentation to a healthcare professional, intentions to seek help, quality of life, adverse effects of the interventions, stages of breast cancer, survival estimates or breast cancer mortality rates. Based on the results of two RCTs, a brief intervention has the potential to increase women’s breast cancer awareness. However, findings of this review should be interpreted with caution, as GRADE assessment identified moderate-quality evidence in only one of the two studies reviewed. In addition, the included trials were heterogeneous in terms of the interventions, population studied and outcomes measured. Therefore, current evidence cannot be generalised to the wider context. Further studies including larger samples, validated outcome measures and longitudinal approaches are warranted. Interventions de sensibilisation des femmes au cancer du sein Le cancer du sein reste le cancer le plus fréquemment diagnostiqué chez les femmes dans le monde entier. Les dépistage, diagnostic et traitement précoces du cancer du sein sont essentiels pour de meilleurs résultats. Puisque de nombreuses femmes découvriront un symptôme mammaire elles-mêmes, il est important qu'elles soient sensibilisées au cancer du sein, c'est-à-dire qu'elles aient les connaissances, les compétences et la confiance de détecter des changements mammaires et de consulter un professionnel de santé immédiatement. Évaluer l'efficacité des interventions visant à sensibiliser les femmes au cancer du sein. Nous avons effectué des recherches dans le registre spécialisé du groupe Cochrane sur le cancer du sein (recherche effectuée le 25 janvier 2016), le registre Cochrane des essais contrôlés (CENTRAL, numéro 2015, édition 12) de la Bibliothèque Cochrane (recherche effectuée le 27 janvier 2016), OvidSP MEDLINE (de 2008 au 27 janvier 2016), Embase (Embase.com, 2008 au 27 janvier 2016), le portail de recherche du Système d'enregistrement international des essais cliniques (ICTRP) de l'Organisation mondiale de la santé et ClinicalTrials.gov (recherche effectuée le 27 février 2016). Nous avons également effectué des recherches dans les références bibliographiques d'articles et de revues identifiés et la littérature grise pour les comptes rendus de conférences et les résumés publiés. Aucune restriction de langue n'a été appliquée. Les essais contrôlés randomisés (ECR) portant sur des interventions pour la sensibilisation des femmes au cancer du sein, c'est-à-dire les connaissances des changements/symptômes potentiels du cancer du sein et la confiance pour s'examiner et palper la poitrine, par tous les moyens de communication, c'est-à-dire individuellement, en groupe, par campagne(s) médiatique(s). Deux auteurs ont indépendamment sélectionné les études, extrait les données et évalué le risque de biais. Nous avons rapporté le rapport des cotes (RC) et les intervalles de confiance à 95 % (IC) pour les résultats dichotomiques et la différence moyenne (DM) et l'écart type (SD) pour les résultats continus. Étant donné qu'il n'a pas été possible de combiner les données issues des études incluses en raison de leur hétérogénéité, nous présentons une synthèse narrative. Nous avons évalué la qualité des preuves en utilisant l'approche GRADE. Nous avons inclus deux ECR portant sur 997 femmes : un ECR (867 femmes) randomisait les femmes pour recevoir une brochure et les soins habituels (groupe expérimental 1), une brochure et les soins habituels ainsi qu'un entretien avec un(e) manipulateur(trice) radio ou un(e) psychologue chercheur (groupe expérimental 2) ou les soins habituels (groupe témoin) ; et le deuxième ECR (130 femmes) randomisait les femmes entre un programme éducatif (trois séances de 60 à 90 minutes) ou l'absence d'intervention (groupe témoin). Connaissance des symptômes du cancer du sein Dans la première étude, les connaissances des symptômes autres qu'une grosseur ont augmenté dans le groupe expérimental 1 par rapport au groupe témoin deux ans après l'intervention, mais pas de manière significative (RC 1,1, IC à 95 % 0,7 à 1,6 ; P = 0,66 ; 449 femmes ; preuves de qualité moyenne). De même, deux ans après l'intervention, les connaissances des symptômes ont augmenté dans le groupe expérimental 2 par rapport au groupe témoin, mais pas de manière significative (RC 1,4, IC à 95 % 0,9 à 2,1 ; P = 0,11 ; 434 femmes ; preuves de qualité moyenne). Dans la deuxième étude, la sensibilisation aux symptômes du cancer du sein a augmenté un mois après l'intervention dans le groupe ayant reçu la formation (DM 3,45, SD 5,11 ; 65 femmes ; preuves de faible qualité) par rapport au groupe témoin (DM −0,68, SD 5,93 ; 65 femmes ; P < 0,001), dans lequel il y avait une diminution de la sensibilisation. Connaissance du risque lié à l'âge Dans la première étude, les connaissances du risque de cancer du sein lié à l'âge des femmes ont augmenté , mais pas significativement, dans le groupe expérimental 1 par rapport au groupe témoin deux ans après l'intervention (RC 1,8 ; IC à 95 % 0,9 à 3,5 ; P < 0,08 ; 447 femmes ; preuves de qualité moyenne). Les connaissances des femmes en matière de risque ont augmenté significativement dans le groupe expérimental 2 par rapport au groupe témoin deux ans après l'intervention (RC 4,8, IC à 95 % 2,6 à 9,0 ; P < 0,001 ; 431 femmes ; preuves de qualité moyenne). Dans la deuxième étude, la vulnérabilité au cancer du sein perçue par les femmes (à quel point elles se considèrent à risque) avait augmenté significativement un mois après l'intervention dans le groupe ayant reçu la formation (DM 1,31, SD 3,57 ; 65 femmes ; preuves de faible qualité) par rapport au groupe témoin (DM −0,55, SD 3,31 ; 65 femmes ; P = 0,005), dans lequel une diminution de la vulnérabilité perçue a été notée. Fréquence des examens mammaires Dans la première étude, aucun changement significatif n'a été noté pour le groupe expérimental 1 par rapport au groupe témoin deux ans après l'intervention (RC 1,1, IC à 95 % 0,8 à 1,6 ; P = 0,54 ; 457 femmes ; preuves de qualité moyenne). Le nombre d'examens mammaires mensuels a augmenté, mais pas de manière significative dans le groupe expérimental 2 par rapport au groupe témoin deux après l'intervention (RC 1,3, IC à 95 % 0,9 à 1,9 ; P = 0,14 ; 445 femmes ; preuves de qualité moyenne). Dans la deuxième étude, les comportements préventifs des femmes en matière de cancer du sein ont augmenté significativement un mois après l'intervention dans le groupe ayant suivi la formation (DM 1,21, SD 2,54 ; 65 femmes ; preuves de faible qualité) par rapport au groupe témoin (DM 0,15, SD 2,94 ; 65 femmes ; P < 0,045). Sensibilisation au cancer du sein La sensibilisation globale des femmes au cancer du sein n'a pas changé dans le groupe expérimental 1 par rapport au groupe témoin deux ans après l'intervention (RC 1,8, IC à 95 % 0,6 à 5,30 ; P = 0,32 ; 435 femmes ; preuves de qualité moyenne), tandis que la sensibilisation globale a augmenté dans le groupe expérimental 2 par rapport au groupe témoin deux ans après l'intervention (RC 8,1, IC à 95 % 2,7 à 25,0 ; P < 0,001 ; 420 femmes ; preuves de qualité moyenne). Dans la deuxième étude, il y avait une augmentation significative des scores sur le modèle Health Belief Model (qui incluait les concepts de connaissance et de vulnérabilité perçue) un mois après l'intervention dans le groupe ayant suivi la formation (moyenne de 1,21, SD 2,54 ; 65 femmes) par rapport au groupe témoin (moyenne de 0,15, SD 2,94 ; 65 femmes ; P = 0,045). Aucune étude n'a rapporté de résultats liés à la motivation relative à l'auto-examen des seins, la confiance pour chercher de l'aide, le temps entre la découverte des symptômes mammaires et la consultation d'un professionnel de santé, les intentions de chercher de l'aide, la qualité de vie, les effets indésirables des interventions, les stades de cancer du sein, les estimations du taux de survie ou du taux de mortalité du cancer du sein. Sur la base des résultats de deux ECR, une intervention brève a le potentiel de sensibiliser les femmes au cancer du sein. Cependant, les résultats de cette revue doivent être interprétés avec prudence, car l'évaluation GRADE a identifié des preuves de qualité moyenne dans une seule des deux études examinées. En outre, les essais inclus étaient hétérogènes en ce qui concerne les interventions, les populations étudiées et les résultats mesurés. Par conséquent, les preuves actuelles ne peuvent pas être généralisées dans un contexte plus large. Des études supplémentaires portant sur de plus grands échantillons et utilisant des mesures validées des résultats et des approches longitudinales sont nécessaires. Traduction réalisée par Sophie Fleurdépine et révisée par Cochrane France
- 10 February 2017
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (2) , CD011396
Interventions for raising breast cancer awareness in women
Breast cancer continues to be the most commonly diagnosed cancer in women globally. Early detection, diagnosis and treatment of breast cancer are key to better outcomes. Since many women will discover a breast cancer symptom themselves, it is important that they are breast cancer aware i.e. have the knowledge, skills and confidence to detect breast changes and present promptly to a healthcare professional. To assess the effectiveness of interventions for raising breast cancer awareness in women. We searched the Cochrane Breast Cancer Group's Specialised Register (searched 25 January 2016), Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 12) in the Cochrane Library (searched 27 January 2016), MEDLINE OvidSP (2008 to 27 January 2016), Embase (Embase.com, 2008 to 27 January 2016), the World Health Organization’s International Clinical Trials Registry Platform (ICTRP) search portal and ClinicalTrials.gov (searched 27 Feburary 2016). We also searched the reference lists of identified articles and reviews and the grey literature for conference proceedings and published abstracts. No language restriction was applied. Randomised controlled trials (RCTs) focusing on interventions for raising women’s breast cancer awareness i.e. knowledge of potential breast cancer symptoms/changes and the confidence to look at and feel their breasts, using any means of delivery, i.e. one-to-one/group/mass media campaign(s). Two authors selected studies, independently extracted data and assessed risk of bias. We reported the odds ratio (OR) and 95% confidence intervals (CIs) for dichotomous outcomes and mean difference (MD) and standard deviation (SD) for continuous outcomes. Since it was not possible to combine data from included studies due to their heterogeneity, we present a narrative synthesis. We assessed the quality of evidence using GRADE methods. We included two RCTs involving 997 women: one RCT (867 women) randomised women to receive either a written booklet and usual care (intervention group 1), a written booklet and usual care plus a verbal interaction with a radiographer or research psychologist (intervention group 2) or usual care (control group); and the second RCT (130 women) randomised women to either an educational programme (three sessions of 60 to 90 minutes) or no intervention (control group). Knowledge of breast cancer symptoms In the first study, knowledge of non-lump symptoms increased in intervention group 1 compared to the control group at two years postintervention, but not significantly (OR 1.1, 95% CI 0.7 to 1.6; P = 0.66; 449 women; moderate-quality evidence). Similarly, at two years postintervention, knowledge of symptoms increased in the intervention group 2 compared to the control group but not significantly (OR 1.4, 95% CI 0.9 to 2.1; P = 0.11; 434 women; moderate-quality evidence). In the second study, women’s awareness of breast cancer symptoms had increased one month post intervention in the educational group (MD 3.45, SD 5.11; 65 women; low-quality evidence) compared to the control group (MD −0.68, SD 5.93; 65 women; P < 0.001), where there was a decrease in awareness. Knowledge of age-related risk In the first study, women’s knowledge of age-related risk of breast cancer increased, but not significantly, in intervention group 1 compared to control at two years postintervention (OR 1.8; 95% CI 0.9 to 3.5; P < 0.08; 447 women; moderate-quality evidence). Women's knowledge of risk increased significantly in intervention group 2 compared to control at two years postintervention (OR 4.8, 95% CI 2.6 to 9.0; P < 0.001; 431 women; moderate-quality evidence). In the second study, women’s perceived susceptibility (how at risk they considered themselves) to breast cancer had increased significantly one month post intervention in the educational group (MD 1.31, SD 3.57; 65 women; low-quality evidence) compared to the control group (MD −0.55, SD 3.31; 65 women; P = 0.005), where a decrease in perceived susceptibility was noted. Frequency of Breast Checking In the first study, no significant change was noted for intervention group 1 compared to control at two years postintervention (OR 1.1, 95% CI 0.8 to 1.6; P = 0.54; 457 women; moderate-quality evidence). Monthly breast checking increased, but not significantly, in intervention group 2 compared to control at two years postintervention (OR 1.3, 95% CI 0.9 to 1.9; P = 0.14; 445 women; moderate-quality evidence). In the second study, women’s breast cancer preventive behaviours increased significantly one month post intervention in the educational group (MD 1.21, SD 2.54; 65 women; low-quality evidence) compared to the control group (MD 0.15, SD 2.94; 65 women; P < 0.045). Breast Cancer Awareness Women’s overall breast cancer awareness did not change in intervention group 1 compared to control at two years postintervention (OR 1.8, 95% CI 0.6 to 5.30; P = 0.32; 435 women; moderate-quality evidence) while overall awareness increased in the intervention group 2 compared to control at two years postintervention (OR 8.1, 95% CI 2.7 to 25.0; P < 0.001; 420 women; moderate-quality evidence). In the second study, there was a significant increase in scores on the Health Belief Model (that included the constructs of awareness and perceived susceptibility) at one month postintervention in the educational group (mean 1.21, SD 2.54; 65 women) compared to the control group (mean 0.15, SD 2.94; 65 women; P = 0.045). Neither study reported outcomes relating to motivation to check their breasts, confidence to seek help, time from breast symptom discovery to presentation to a healthcare professional, intentions to seek help, quality of life, adverse effects of the interventions, stages of breast cancer, survival estimates or breast cancer mortality rates. Based on the results of two RCTs, a brief intervention has the potential to increase women’s breast cancer awareness. However, findings of this review should be interpreted with caution, as GRADE assessment identified moderate-quality evidence in only one of the two studies reviewed. In addition, the included trials were heterogeneous in terms of the interventions, population studied and outcomes measured. Therefore, current evidence cannot be generalised to the wider context. Further studies including larger samples, validated outcome measures and longitudinal approaches are warranted. Interventions de sensibilisation des femmes au cancer du sein Le cancer du sein reste le cancer le plus fréquemment diagnostiqué chez les femmes dans le monde entier. Les dépistage, diagnostic et traitement précoces du cancer du sein sont essentiels pour de meilleurs résultats. Puisque de nombreuses femmes découvriront un symptôme mammaire elles-mêmes, il est important qu'elles soient sensibilisées au cancer du sein, c'est-à-dire qu'elles aient les connaissances, les compétences et la confiance de détecter des changements mammaires et de consulter un professionnel de santé immédiatement. Évaluer l'efficacité des interventions visant à sensibiliser les femmes au cancer du sein. Nous avons effectué des recherches dans le registre spécialisé du groupe Cochrane sur le cancer du sein (recherche effectuée le 25 janvier 2016), le registre Cochrane des essais contrôlés (CENTRAL, numéro 2015, édition 12) de la Bibliothèque Cochrane (recherche effectuée le 27 janvier 2016), OvidSP MEDLINE (de 2008 au 27 janvier 2016), Embase (Embase.com, 2008 au 27 janvier 2016), le portail de recherche du Système d'enregistrement international des essais cliniques (ICTRP) de l'Organisation mondiale de la santé et ClinicalTrials.gov (recherche effectuée le 27 février 2016). Nous avons également effectué des recherches dans les références bibliographiques d'articles et de revues identifiés et la littérature grise pour les comptes rendus de conférences et les résumés publiés. Aucune restriction de langue n'a été appliquée. Les essais contrôlés randomisés (ECR) portant sur des interventions pour la sensibilisation des femmes au cancer du sein, c'est-à-dire les connaissances des changements/symptômes potentiels du cancer du sein et la confiance pour s'examiner et palper la poitrine, par tous les moyens de communication, c'est-à-dire individuellement, en groupe, par campagne(s) médiatique(s). Deux auteurs ont indépendamment sélectionné les études, extrait les données et évalué le risque de biais. Nous avons rapporté le rapport des cotes (RC) et les intervalles de confiance à 95 % (IC) pour les résultats dichotomiques et la différence moyenne (DM) et l'écart type (SD) pour les résultats continus. Étant donné qu'il n'a pas été possible de combiner les données issues des études incluses en raison de leur hétérogénéité, nous présentons une synthèse narrative. Nous avons évalué la qualité des preuves en utilisant l'approche GRADE. Nous avons inclus deux ECR portant sur 997 femmes : un ECR (867 femmes) randomisait les femmes pour recevoir une brochure et les soins habituels (groupe expérimental 1), une brochure et les soins habituels ainsi qu'un entretien avec un(e) manipulateur(trice) radio ou un(e) psychologue chercheur (groupe expérimental 2) ou les soins habituels (groupe témoin) ; et le deuxième ECR (130 femmes) randomisait les femmes entre un programme éducatif (trois séances de 60 à 90 minutes) ou l'absence d'intervention (groupe témoin). Connaissance des symptômes du cancer du sein Dans la première étude, les connaissances des symptômes autres qu'une grosseur ont augmenté dans le groupe expérimental 1 par rapport au groupe témoin deux ans après l'intervention, mais pas de manière significative (RC 1,1, IC à 95 % 0,7 à 1,6 ; P = 0,66 ; 449 femmes ; preuves de qualité moyenne). De même, deux ans après l'intervention, les connaissances des symptômes ont augmenté dans le groupe expérimental 2 par rapport au groupe témoin, mais pas de manière significative (RC 1,4, IC à 95 % 0,9 à 2,1 ; P = 0,11 ; 434 femmes ; preuves de qualité moyenne). Dans la deuxième étude, la sensibilisation aux symptômes du cancer du sein a augmenté un mois après l'intervention dans le groupe ayant reçu la formation (DM 3,45, SD 5,11 ; 65 femmes ; preuves de faible qualité) par rapport au groupe témoin (DM −0,68, SD 5,93 ; 65 femmes ; P < 0,001), dans lequel il y avait une diminution de la sensibilisation. Connaissance du risque lié à l'âge Dans la première étude, les connaissances du risque de cancer du sein lié à l'âge des femmes ont augmenté , mais pas significativement, dans le groupe expérimental 1 par rapport au groupe témoin deux ans après l'intervention (RC 1,8 ; IC à 95 % 0,9 à 3,5 ; P < 0,08 ; 447 femmes ; preuves de qualité moyenne). Les connaissances des femmes en matière de risque ont augmenté significativement dans le groupe expérimental 2 par rapport au groupe témoin deux ans après l'intervention (RC 4,8, IC à 95 % 2,6 à 9,0 ; P < 0,001 ; 431 femmes ; preuves de qualité moyenne). Dans la deuxième étude, la vulnérabilité au cancer du sein perçue par les femmes (à quel point elles se considèrent à risque) avait augmenté significativement un mois après l'intervention dans le groupe ayant reçu la formation (DM 1,31, SD 3,57 ; 65 femmes ; preuves de faible qualité) par rapport au groupe témoin (DM −0,55, SD 3,31 ; 65 femmes ; P = 0,005), dans lequel une diminution de la vulnérabilité perçue a été notée. Fréquence des examens mammaires Dans la première étude, aucun changement significatif n'a été noté pour le groupe expérimental 1 par rapport au groupe témoin deux ans après l'intervention (RC 1,1, IC à 95 % 0,8 à 1,6 ; P = 0,54 ; 457 femmes ; preuves de qualité moyenne). Le nombre d'examens mammaires mensuels a augmenté, mais pas de manière significative dans le groupe expérimental 2 par rapport au groupe témoin deux après l'intervention (RC 1,3, IC à 95 % 0,9 à 1,9 ; P = 0,14 ; 445 femmes ; preuves de qualité moyenne). Dans la deuxième étude, les comportements préventifs des femmes en matière de cancer du sein ont augmenté significativement un mois après l'intervention dans le groupe ayant suivi la formation (DM 1,21, SD 2,54 ; 65 femmes ; preuves de faible qualité) par rapport au groupe témoin (DM 0,15, SD 2,94 ; 65 femmes ; P < 0,045). Sensibilisation au cancer du sein La sensibilisation globale des femmes au cancer du sein n'a pas changé dans le groupe expérimental 1 par rapport au groupe témoin deux ans après l'intervention (RC 1,8, IC à 95 % 0,6 à 5,30 ; P = 0,32 ; 435 femmes ; preuves de qualité moyenne), tandis que la sensibilisation globale a augmenté dans le groupe expérimental 2 par rapport au groupe témoin deux ans après l'intervention (RC 8,1, IC à 95 % 2,7 à 25,0 ; P < 0,001 ; 420 femmes ; preuves de qualité moyenne). Dans la deuxième étude, il y avait une augmentation significative des scores sur le modèle Health Belief Model (qui incluait les concepts de connaissance et de vulnérabilité perçue) un mois après l'intervention dans le groupe ayant suivi la formation (moyenne de 1,21, SD 2,54 ; 65 femmes) par rapport au groupe témoin (moyenne de 0,15, SD 2,94 ; 65 femmes ; P = 0,045). Aucune étude n'a rapporté de résultats liés à la motivation relative à l'auto-examen des seins, la confiance pour chercher de l'aide, le temps entre la découverte des symptômes mammaires et la consultation d'un professionnel de santé, les intentions de chercher de l'aide, la qualité de vie, les effets indésirables des interventions, les stades de cancer du sein, les estimations du taux de survie ou du taux de mortalité du cancer du sein. Sur la base des résultats de deux ECR, une intervention brève a le potentiel de sensibiliser les femmes au cancer du sein. Cependant, les résultats de cette revue doivent être interprétés avec prudence, car l'évaluation GRADE a identifié des preuves de qualité moyenne dans une seule des deux études examinées. En outre, les essais inclus étaient hétérogènes en ce qui concerne les interventions, les populations étudiées et les résultats mesurés. Par conséquent, les preuves actuelles ne peuvent pas être généralisées dans un contexte plus large. Des études supplémentaires portant sur de plus grands échantillons et utilisant des mesures validées des résultats et des approches longitudinales sont nécessaires. Traduction réalisée par Sophie Fleurdépine et révisée par Cochrane France
- 18 June 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 6,p. CD010720
Needle size for vaccination procedures in children and adolescents
Hypodermic needles of different sizes (gauges and lengths) can be used for vaccination procedures. The gauge (G) refers to the outside diameter of the needle tubing. The higher the gauge number, the smaller diameter of the needle (eg a 25 G needle is 0.5 mm in diameter and is narrower than a 23 G needle (0.6 mm)). Many vaccines are recommended for injection into muscle (intramuscularly), although some are delivered subcutaneously (under the skin) and intradermally (into skin). Choosing an appropriate length and gauge of a needle may be important to ensure that a vaccine is delivered to the appropriate site and produces the maximum immune response while causing the least possible harm. There are some conflicting guidelines regarding the lengths and gauges of needles that should be used for vaccination procedures in children and adolescents. To assess the effects of using needles of different lengths and gauges for administering vaccines to children and adolescents on vaccine immunogenicity (the ability of the vaccine to elicit an immune response), procedural pain, and other reactogenicity events (adverse events following vaccine administration). We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library 2014, Issue 10), MEDLINE and MEDLINE in Progress via Ovid (1947 to November 2014), EMBASE via Ovid (1974 to November 2014), and CINAHL via EBSCOhost (1982 to November 2014). We also searched reference lists of articles and textbooks, the proceedings of vaccine conferences, and three clinical trial registers. Randomised controlled trials evaluating the effects of using hypodermic needles of any gauge or length to administer any type of vaccine to people aged from birth to 24 years. Three review authors independently extracted trial data and assessed the risk of bias. We contacted trial authors for additional information. We rated the quality of evidence using the GRADE system. We included five trials involving 1350 participants. Data for the primary review outcomes were either absent (for the incidence of vaccine-preventable diseases) or limited (for procedural pain and crying). The available evidence was compromised by the use of surrogate immunogenicity outcomes, incomplete blinding of outcome assessors, and imprecision for some outcomes. The evidence from two small trials was insufficient to allow any confident statements to be made about the effects of the needles evaluated in the trials on vaccine immunogenicity and reactogenicity.The remaining three trials (1135 participants) contributed data to comparisons between 25 G 25 mm, 23 G 25 mm, and 25 G 16 mm needles. These trials involved infants predominantly aged two to six months undergoing intramuscular vaccination in the anterolateral thigh using the World Health Organization (WHO) injection technique (skin stretched flat, needle inserted at a 90° angle and up to the needle hub in healthy infants). The vaccines administered were combination vaccines containing diphtheria, tetanus, and whole-cell pertussis antigens (DTwP). In some trials, the vaccines also contained Haemophilus influenzae type b (DTwP-Hib) and hepatitis B (DTwP-Hib-HepB) antigen components.We found moderate quality evidence from one trial that there is probably little or no difference in immune response, defined in terms of the proportion of seroprotected infants, between using 25 G 25 mm, 23 G 25 mm, or 25 G 16 mm needles to administer a series of three doses of a DTwP-Hib vaccine at ages two, three, and four months (numbers of participants in analyses range from 309 to 402. Immune response to pertussis antigen not measured).25 mm needles (either 23 G or 25 G) probably lead to fewer severe local reactions (extensive redness and swelling) and fewer non-severe local reactions (any redness, swelling, tenderness or hardness (composite outcome)) after DTwP-Hib vaccination compared with 25 G 16 mm needles. We estimate that one fewer infant will experience a severe local reaction after the first vaccine dose for every 25 infants vaccinated with the longer rather than the shorter needle (number needed to treat (NNT) 25 (95% confidence interval (CI) 15 to 100)). We estimate that one fewer infant will experience a non-severe local reaction at 24 hours after the first, second, and third vaccine doses for every five to eight infants vaccinated with the longer rather than the shorter needle (NNTs range from 5 (95% CI 4 to 10) to 8 (95% CI 5 to 34)) (moderate quality evidence, one trial for first and second doses, two trials for third dose, numbers of participants in analyses range from 413 to 528).Using a wider gauge needle (23 G 25 mm) may slightly reduce procedural pain (low quality evidence) and probably leads to a slight reduction in the duration of crying time immediately after vaccination (moderate quality evidence) compared with a narrower gauge (25 G 25 mm) needle (one trial, 320 participants). The effects are probably not large enough to be of any clinical relevance. The 25 G 25 mm needle may produce a small reduction in the incidence of local reactions after each dose of a DTwP vaccine compared with the 23 G 25 mm needle, but the effect estimates are imprecise (low quality evidence, two trials, numbers of participants in analyses range from 100 to 459).The comparative effects of 23 G 25 mm, 25 G 25 mm, and 25 G 16 mm needles on the incidence of post-vaccination fever, persistent inconsolable crying, and other systemic events such as drowsiness, loss of appetite, and vomiting are uncertain due to the very low quality of the evidence. Using 25 mm needles (either 23 G or 25 G) for intramuscular vaccination procedures in the anterolateral thigh of infants using the WHO injection technique probably reduces the occurrence of local reactions while achieving a comparable immune response to 25 G 16 mm needles. These findings are applicable to healthy infants aged two to six months receiving combination DTwP vaccines with a reactogenic whole-cell...
- 18 June 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 6,p. CD010720
Needle size for vaccination procedures in children and adolescents
Hypodermic needles of different sizes (gauges and lengths) can be used for vaccination procedures. The gauge (G) refers to the outside diameter of the needle tubing. The higher the gauge number, the smaller diameter of the needle (eg a 25 G needle is 0.5 mm in diameter and is narrower than a 23 G needle (0.6 mm)). Many vaccines are recommended for injection into muscle (intramuscularly), although some are delivered subcutaneously (under the skin) and intradermally (into skin). Choosing an appropriate length and gauge of a needle may be important to ensure that a vaccine is delivered to the appropriate site and produces the maximum immune response while causing the least possible harm. There are some conflicting guidelines regarding the lengths and gauges of needles that should be used for vaccination procedures in children and adolescents. To assess the effects of using needles of different lengths and gauges for administering vaccines to children and adolescents on vaccine immunogenicity (the ability of the vaccine to elicit an immune response), procedural pain, and other reactogenicity events (adverse events following vaccine administration). We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library 2014, Issue 10), MEDLINE and MEDLINE in Progress via Ovid (1947 to November 2014), EMBASE via Ovid (1974 to November 2014), and CINAHL via EBSCOhost (1982 to November 2014). We also searched reference lists of articles and textbooks, the proceedings of vaccine conferences, and three clinical trial registers. Randomised controlled trials evaluating the effects of using hypodermic needles of any gauge or length to administer any type of vaccine to people aged from birth to 24 years. Three review authors independently extracted trial data and assessed the risk of bias. We contacted trial authors for additional information. We rated the quality of evidence using the GRADE system. We included five trials involving 1350 participants. Data for the primary review outcomes were either absent (for the incidence of vaccine-preventable diseases) or limited (for procedural pain and crying). The available evidence was compromised by the use of surrogate immunogenicity outcomes, incomplete blinding of outcome assessors, and imprecision for some outcomes. The evidence from two small trials was insufficient to allow any confident statements to be made about the effects of the needles evaluated in the trials on vaccine immunogenicity and reactogenicity.The remaining three trials (1135 participants) contributed data to comparisons between 25 G 25 mm, 23 G 25 mm, and 25 G 16 mm needles. These trials involved infants predominantly aged two to six months undergoing intramuscular vaccination in the anterolateral thigh using the World Health Organization (WHO) injection technique (skin stretched flat, needle inserted at a 90° angle and up to the needle hub in healthy infants). The vaccines administered were combination vaccines containing diphtheria, tetanus, and whole-cell pertussis antigens (DTwP). In some trials, the vaccines also contained Haemophilus influenzae type b (DTwP-Hib) and hepatitis B (DTwP-Hib-HepB) antigen components.We found moderate quality evidence from one trial that there is probably little or no difference in immune response, defined in terms of the proportion of seroprotected infants, between using 25 G 25 mm, 23 G 25 mm, or 25 G 16 mm needles to administer a series of three doses of a DTwP-Hib vaccine at ages two, three, and four months (numbers of participants in analyses range from 309 to 402. Immune response to pertussis antigen not measured).25 mm needles (either 23 G or 25 G) probably lead to fewer severe local reactions (extensive redness and swelling) and fewer non-severe local reactions (any redness, swelling, tenderness or hardness (composite outcome)) after DTwP-Hib vaccination compared with 25 G 16 mm needles. We estimate that one fewer infant will experience a severe local reaction after the first vaccine dose for every 25 infants vaccinated with the longer rather than the shorter needle (number needed to treat (NNT) 25 (95% confidence interval (CI) 15 to 100)). We estimate that one fewer infant will experience a non-severe local reaction at 24 hours after the first, second, and third vaccine doses for every five to eight infants vaccinated with the longer rather than the shorter needle (NNTs range from 5 (95% CI 4 to 10) to 8 (95% CI 5 to 34)) (moderate quality evidence, one trial for first and second doses, two trials for third dose, numbers of participants in analyses range from 413 to 528).Using a wider gauge needle (23 G 25 mm) may slightly reduce procedural pain (low quality evidence) and probably leads to a slight reduction in the duration of crying time immediately after vaccination (moderate quality evidence) compared with a narrower gauge (25 G 25 mm) needle (one trial, 320 participants). The effects are probably not large enough to be of any clinical relevance. The 25 G 25 mm needle may produce a small reduction in the incidence of local reactions after each dose of a DTwP vaccine compared with the 23 G 25 mm needle, but the effect estimates are imprecise (low quality evidence, two trials, numbers of participants in analyses range from 100 to 459).The comparative effects of 23 G 25 mm, 25 G 25 mm, and 25 G 16 mm needles on the incidence of post-vaccination fever, persistent inconsolable crying, and other systemic events such as drowsiness, loss of appetite, and vomiting are uncertain due to the very low quality of the evidence. Using 25 mm needles (either 23 G or 25 G) for intramuscular vaccination procedures in the anterolateral thigh of infants using the WHO injection technique probably reduces the occurrence of local reactions while achieving a comparable immune response to 25 G 16 mm needles. These findings are applicable to healthy infants aged two to six months receiving combination DTwP vaccines with a reactogenic whole-cell...
- 8 September 2014
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (6) , CD007641
Self-management education for cystic fibrosis
Self-management education may help patients with cystic fibrosis and their families to choose, monitor and adjust treatment requirements for their illness, and also to manage the effects of illness on their lives. Although self-management education interventions have been developed for cystic fibrosis, no previous systematic review of the evidence of effectiveness of these interventions has been conducted. To assess the effects of self-management education interventions on improving health outcomes for patients with cystic fibrosis and their caregivers We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register (date of the last search: 22 August 2013).We also searched databases through EBSCO (CINAHL; Psychological and Behavioural Sciences Collection; PsychInfo; SocINDEX) and Elsevier (Embase) and handsearched relevant journals and conference proceedings (date of the last searches: 01 February 2014 ). Randomised controlled trials, quasi-randomised controlled trials or controlled clinical trials comparing different types of self-management education for cystic fibrosis or comparing self-management education with standard care or no intervention. Two authors assessed trial eligibility and risk of bias. Three authors extracted data. Four trials (involving a total of 269 participants) were included. The participants were children with cystic fibrosis and their parents or caregivers in three trials and adults with cystic fibrosis in one trial. The trials compared four different self-management education interventions versus standard treatment: (1) a training programme for managing cystic fibrosis in general; (2) education specific to aerosol and airway clearance treatments; (3) disease-specific nutrition education; and (4) general and disease-specific nutrition education. Training children to manage cystic fibrosis in general had no statistically significant effects on weight after six to eight weeks, mean difference -7.74 lb (i.e. 3.51 kg) (95% confidence interval -35.18 to 19.70). General and disease-specific nutrition education for adults had no statistically significant effects on: pulmonary function (forced expiratory volume at one second), mean difference -5.00 % (95% confidence interval -18.10 to 8.10) at six months and mean difference -5.50 % (95% confidence interval -18.46 to 7.46) at 12 months; or weight, mean difference - 0.70 kg (95% confidence interval -6.58 to 5.18) at six months and mean difference -0.70 kg (95% confidence interval -6.62 to 5.22) at 12 months; or dietary fat intake scores, mean difference 1.60 (85% confidence interval -2.90 to 6.10) at six months and mean difference 0.20 (95% confidence interval -4.08 to 4.48) at 12 months. There is some limited evidence to suggest that self-management education may improve knowledge in patients with cystic fibrosis but not in parents or caregivers. There is also some limited evidence to suggest that self-management education may result in positively changing a small number of behaviours in both patients and caregivers. The available evidence from this review is of insufficient quantity and quality to draw any firm conclusions about the effects of self-management education for cystic fibrosis. Further trials are needed to investigate the effects of self-management education on a range of clinical and behavioural outcomes in children, adolescents and adults with cystic fibrosis and their caregivers.
- 8 September 2014
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (6) , CD007641
Self-management education for cystic fibrosis
Self-management education may help patients with cystic fibrosis and their families to choose, monitor and adjust treatment requirements for their illness, and also to manage the effects of illness on their lives. Although self-management education interventions have been developed for cystic fibrosis, no previous systematic review of the evidence of effectiveness of these interventions has been conducted. To assess the effects of self-management education interventions on improving health outcomes for patients with cystic fibrosis and their caregivers We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register (date of the last search: 22 August 2013).We also searched databases through EBSCO (CINAHL; Psychological and Behavioural Sciences Collection; PsychInfo; SocINDEX) and Elsevier (Embase) and handsearched relevant journals and conference proceedings (date of the last searches: 01 February 2014 ). Randomised controlled trials, quasi-randomised controlled trials or controlled clinical trials comparing different types of self-management education for cystic fibrosis or comparing self-management education with standard care or no intervention. Two authors assessed trial eligibility and risk of bias. Three authors extracted data. Four trials (involving a total of 269 participants) were included. The participants were children with cystic fibrosis and their parents or caregivers in three trials and adults with cystic fibrosis in one trial. The trials compared four different self-management education interventions versus standard treatment: (1) a training programme for managing cystic fibrosis in general; (2) education specific to aerosol and airway clearance treatments; (3) disease-specific nutrition education; and (4) general and disease-specific nutrition education. Training children to manage cystic fibrosis in general had no statistically significant effects on weight after six to eight weeks, mean difference -7.74 lb (i.e. 3.51 kg) (95% confidence interval -35.18 to 19.70). General and disease-specific nutrition education for adults had no statistically significant effects on: pulmonary function (forced expiratory volume at one second), mean difference -5.00 % (95% confidence interval -18.10 to 8.10) at six months and mean difference -5.50 % (95% confidence interval -18.46 to 7.46) at 12 months; or weight, mean difference - 0.70 kg (95% confidence interval -6.58 to 5.18) at six months and mean difference -0.70 kg (95% confidence interval -6.62 to 5.22) at 12 months; or dietary fat intake scores, mean difference 1.60 (85% confidence interval -2.90 to 6.10) at six months and mean difference 0.20 (95% confidence interval -4.08 to 4.48) at 12 months. There is some limited evidence to suggest that self-management education may improve knowledge in patients with cystic fibrosis but not in parents or caregivers. There is also some limited evidence to suggest that self-management education may result in positively changing a small number of behaviours in both patients and caregivers. The available evidence from this review is of insufficient quantity and quality to draw any firm conclusions about the effects of self-management education for cystic fibrosis. Further trials are needed to investigate the effects of self-management education on a range of clinical and behavioural outcomes in children, adolescents and adults with cystic fibrosis and their caregivers.
- 1 May 2014
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 204 (5) , 383-390
Group problem-solving skills training for self-harm: randomised controlled trial
Background: Rates of self-harm are high and have recently increased. This trend and the repetitive nature of self-harm pose a significant challenge to mental health services.Aims: To determine the efficacy of a structured group problem-solving skills training (PST) programme as an intervention approach for self-harm in addition to treatment as usual (TAU) as offered by mental health services.Method: A total of 433 participants (aged 18–64 years) were randomly assigned to TAU plus PST or TAU alone. Assessments were carried out at baseline and at 6-week and 6-month follow-up and repeated hospital-treated self-harm was ascertained at 12-month follow-up.Results: The treatment groups did not differ in rates of repeated self-harm at 6-week, 6-month and 12-month follow-up. Both treatment groups showed significant improvements in psychological and social functioning at follow-up. Only one measure (needing and receiving practical help from those closest to them) showed a positive treatment effect at 6-week (P= 0.004) and 6-month (P= 0.01) follow-up. Repetition was not associated with waiting time in the PST group.Conclusions: This brief intervention for self-harm is no more effective than treatment as usual. Further work is required to establish whether a modified, more intensive programme delivered sooner after the index episode would be effective.
- 1 May 2014
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 204 (5) , 383-390
Group problem-solving skills training for self-harm: randomised controlled trial
Background: Rates of self-harm are high and have recently increased. This trend and the repetitive nature of self-harm pose a significant challenge to mental health services.Aims: To determine the efficacy of a structured group problem-solving skills training (PST) programme as an intervention approach for self-harm in addition to treatment as usual (TAU) as offered by mental health services.Method: A total of 433 participants (aged 18–64 years) were randomly assigned to TAU plus PST or TAU alone. Assessments were carried out at baseline and at 6-week and 6-month follow-up and repeated hospital-treated self-harm was ascertained at 12-month follow-up.Results: The treatment groups did not differ in rates of repeated self-harm at 6-week, 6-month and 12-month follow-up. Both treatment groups showed significant improvements in psychological and social functioning at follow-up. Only one measure (needing and receiving practical help from those closest to them) showed a positive treatment effect at 6-week (P= 0.004) and 6-month (P= 0.01) follow-up. Repetition was not associated with waiting time in the PST group.Conclusions: This brief intervention for self-harm is no more effective than treatment as usual. Further work is required to establish whether a modified, more intensive programme delivered sooner after the index episode would be effective.
- 27 August 2013
- Published by Wiley
- No. 8
Needle size for vaccination procedures in children and adolescents
- 27 August 2013
- Published by Wiley
- No. 8
Needle size for vaccination procedures in children and adolescents
- 10 November 2010
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 11,p. CD006590
Radical prostatectomy versus watchful waiting for prostate cancer
Background The lack of evidence regarding the effectiveness of treatment options for clinically localised prostate cancer continues to impact on clinical decision‐making. Two such options are radical prostatectomy (RP) and watchful waiting (WW). WW involves providing no initial treatment and monitoring the patient with the intention of providing palliative treatment if there is evidence of disease progression. Objectives To compare the beneficial and harmful effects of RP versus WW for the treatment of localised prostate cancer. Search methods MEDLINE, EMBASE, The Cochrane Library, ISI Science Citation Index, DARE and LILACS were searched through 30 July 2010. Selection criteria Randomised or quasi‐randomised controlled trials comparing the effects of RP versus WW for clinically localised prostate cancer. Data collection and analysis Data extraction and quality assessment were carried out independently by two authors. Main results Two trials met the inclusion criteria. Both trials commenced prior to the widespread availability of prostate‐specific antigen (PSA) screening; hence the results may not be applicable to men with PSA‐detected disease. One trial (N = 142), conducted in the US, was judged to be of poor quality. All cause (overall) mortality was not significantly different between RP and WW groups after fifteen years of follow up (Hazard Ratio (HR) 0.9 (95% Confidence Interval (CI) 0.56 to 1.43). The second trial (N = 695), conducted in Scandinavia, was judged to be of good quality. After 12 years of follow up, the trial results were compatible with a beneficial effect of RP on the risks of overall mortality, prostate cancer mortality and distant metastases compared with WW but the precise magnitude of the effect is uncertain as indicated by the width of the confidence intervals for all estimates (risk difference (RD) ‐7.1% (95% CI ‐14.7 to 0.5); RD ‐5.4% (95% CI ‐11.1 to 0.2); RD ‐6.7% (95% CI ‐13.2 to ‐0.2), respectively). Compared to WW, RP increased the absolute risks of erectile dysfunction (RD 35% (95% CI 25 to 45)) and urinary leakage (RD 27% (95% CI 17 to 37)). These estimates must be interpreted cautiously as they are derived from data obtained from a self‐administered questionnaire survey of a sample of the trial participants (N = 326), no baseline quality of life data were obtained and nerve‐sparing surgery was not routinely performed on trial participants undergoing RP. Authors' conclusions The existing trials provide insufficient evidence to allow confident statements to be made about the relative beneficial and harmful effects of RP and WW for patients with localised prostate cancer. The results of ongoing trials should help to inform treatment decisions for men with screen‐detected localised prostate cancer.
- 10 November 2010
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 11,p. CD006590
Radical prostatectomy versus watchful waiting for prostate cancer
Background The lack of evidence regarding the effectiveness of treatment options for clinically localised prostate cancer continues to impact on clinical decision‐making. Two such options are radical prostatectomy (RP) and watchful waiting (WW). WW involves providing no initial treatment and monitoring the patient with the intention of providing palliative treatment if there is evidence of disease progression. Objectives To compare the beneficial and harmful effects of RP versus WW for the treatment of localised prostate cancer. Search methods MEDLINE, EMBASE, The Cochrane Library, ISI Science Citation Index, DARE and LILACS were searched through 30 July 2010. Selection criteria Randomised or quasi‐randomised controlled trials comparing the effects of RP versus WW for clinically localised prostate cancer. Data collection and analysis Data extraction and quality assessment were carried out independently by two authors. Main results Two trials met the inclusion criteria. Both trials commenced prior to the widespread availability of prostate‐specific antigen (PSA) screening; hence the results may not be applicable to men with PSA‐detected disease. One trial (N = 142), conducted in the US, was judged to be of poor quality. All cause (overall) mortality was not significantly different between RP and WW groups after fifteen years of follow up (Hazard Ratio (HR) 0.9 (95% Confidence Interval (CI) 0.56 to 1.43). The second trial (N = 695), conducted in Scandinavia, was judged to be of good quality. After 12 years of follow up, the trial results were compatible with a beneficial effect of RP on the risks of overall mortality, prostate cancer mortality and distant metastases compared with WW but the precise magnitude of the effect is uncertain as indicated by the width of the confidence intervals for all estimates (risk difference (RD) ‐7.1% (95% CI ‐14.7 to 0.5); RD ‐5.4% (95% CI ‐11.1 to 0.2); RD ‐6.7% (95% CI ‐13.2 to ‐0.2), respectively). Compared to WW, RP increased the absolute risks of erectile dysfunction (RD 35% (95% CI 25 to 45)) and urinary leakage (RD 27% (95% CI 17 to 37)). These estimates must be interpreted cautiously as they are derived from data obtained from a self‐administered questionnaire survey of a sample of the trial participants (N = 326), no baseline quality of life data were obtained and nerve‐sparing surgery was not routinely performed on trial participants undergoing RP. Authors' conclusions The existing trials provide insufficient evidence to allow confident statements to be made about the relative beneficial and harmful effects of RP and WW for patients with localised prostate cancer. The results of ongoing trials should help to inform treatment decisions for men with screen‐detected localised prostate cancer.